

# Japanese Encephalitis (JE) Vaccine Workgroup Update

---

Lorry Rubin, M.D.  
ACIP, Workgroup Chair

October 21, 2015

# ACIP JE & YF Vaccines Workgroup members

## ACIP

Lorry Rubin, WG Chair

Emmanuel Walter, ACIP

## Ex Officio

Doran Fink, FDA

Mike Holbrook, NIH

Lewis Markoff, FDA

Pat Repik, NIH

Eric Sergienko, DoD

## ACIP liaisons

Elizabeth Barnett, AAP

Robert Schechter, AIM

## CDC

Marc Fischer, DVBD

Mark Gershman, DGMQ

Susan Hills, DVBD

Mike McNeil, ISO

Hardeep Sandhu, GID

Erin Staples, DVBD

## Technical advisors

Alan Barrett, Univ Texas Galveston

Joseph Bocchini, Louisiana State Univ

Lin Chen, Mount Auburn Hosp

Myron Levin, Univ Colorado

Tony Marfin, PATH

Cody Meissner, Tufts Univ

David Shlim, ISTM

Mary Wilson, Harvard Univ

# JE vaccine in the United States

---

- Inactivated Vero cell culture-derived JE vaccine (JE-VC; Ixiaro) is the only JE vaccine available in the U.S.
- JE-VC is manufactured by Valneva (formerly Intercell)
- Inactivated mouse brain–derived vaccine (JE-MB; JE-VAX) is no longer available in the U.S.

# ACIP recommendations for use of JE-VC

---

2009: FDA licensed JE-VC for use in adults and  
ACIP approved recommendations for primary series in adults

---

2010: Updated MMWR Recommendations & Reports from 1993

---

2011: ACIP approved recommendations for booster dose in adults  
and published policy note in MMWR

---

2013: ACIP approved recommendations for primary series in  
children and published policy note in MMWR

---

# ACIP JE Vaccine Workgroup objectives

---

- Review newly available safety and immunogenicity data for JE-VC
- Review epidemiology and risk of JE in travelers
- Review ACIP recommendations for use of JE vaccine in consideration of updated safety, immunogenicity, and traveler risk data
- Update MMWR Recommendations and Reports published in 2010

# Today's JE vaccine presentations

---

- Katrin Dubischar (Valneva Austria GmbH)
  - Change in JE vaccine distributor
  - Immunogenicity in adults  $\geq 65$  years of age
  - Accelerated dosing schedule
  - Concomitant administration with rabies vaccine
- Susan Hills (CDC/NCEZID)
  - ACIP workgroup summary and plans